Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review

Abstract

AbstractIntroductionIn malaria‐stricken regions, malaria continues to be one of the primary causes of mortality for children. The number of malaria‐related fatalities has drastically decreased because of artemisinin‐based pharmacological regimens.MethodsTwo independent researchers did a comprehensive literature search using PubMed/MEDLINE and Google Scholar from its inception to September 2022.ResultsAfter evaluating RTS, S/AS01 for its safety, effectiveness, and feasibility, the European Medicines Agency (EMA) issued a favorable conclusion. It was suggested that the RTS, S malaria vaccine be used extensively by the World Health Organization on October 6, 2021. The successful pilot program testing the malaria vaccine in Ghana, Kenya, and Malawi served as the basis for this proposal.ConclusionSeveral challenges need to be addressed to ensure the success of vaccination programs. From the acceptability perspective, issues such as inadequate community engagement, concerns about side effects, and issues with the delivery and quality of healthcare services can affect the acceptance of the vaccine. From the feasibility standpoint, factors such as lack of transportation or long distances to healthcare facilities and the perception of completion of the vaccination calendar can affect the feasibility of the vaccine. Lastly, the availability of the vaccine is also a major concern as it may not be readily available to meet the demands.